Skip to main content
. 2020 Jun 27;2020:5692829. doi: 10.1155/2020/5692829

Figure 3.

Figure 3

Expression of surface markers on monocytes stimulated with IL-17. Human CD14++CD16− and CD14++CD16+/CD14+CD16++ monocytes were treated with IL-17, IFN-γ, which was used as a positive control, IL-17/IFN-γ, or culture medium alone, which was used as a negative control, for 24 hours. Human CD14++CD16− in STEMI: (a) TLR4, (e) CD86, and (i) HLA-DR. Human CD14++CD16−in post-STEMI: (b) TLR4, (f) CD86, and (j) HLA-DR. Human CD14++CD16+/CD14+CD16++ monocytes in STEMI: (c) TLR4, (g) CD86, and (k) HLA-DR. CD14++CD16+/CD14+CD16++ monocytes post-STEMI: (d) TLR4, (h) CD86, and (l) HLA-DR. Expression levels of TLR4, CD86, and HLA-DR are expressed as MFI. White column: STEMI; black column: post-STEMI; n = 11. ∗p < 0.05.